Reports
Generics and biosimilars can save Ireland Euros 1 billion in five years
Medicines for Ireland (MFI) launched their ‘Reductions in the Cost of Medicines – Ireland’s Patients First 2020–2022’ report on 29 September 2020. This report outlines how additional savings of up to Euros 1 billion in the next five years can be achieved through increased use of generics and biosimilars.
Biosimilar infliximab could save Canada over CA$2 million by 2021
Estimates for the potential savings from the use of infliximab biosimilars in Canada suggests that savings by 2021 could be between CA$447 million and CA$2,310 million, depending on the level of uptake.
Cost savings from biosimilars in Canada: actual and projected
Information from the Patented Medicine Prices Review Board (PMPRB) in Canada details the cost savings that could be made from biosimilars in the country.
Biosimilar infliximab uptake in Canada
The first biosimilar infliximab was sold in Canada in 2015, yet by 2018 uptake was still less then 10%, data from the Patented Medicine Prices Review Board (PMPRB) reveal.
Low levels of biosimilar uptake in Canada
Data from Canada’s Patented Medicine Prices Review Board (PMRPB) reveal an increasing number of biosimilar approvals in recent years, yet Canada lags behind other nations in terms of both approvals and uptake.
US biosimilars pipeline for immunosuppressants, insulin and ophthalmology
Biologicals are becoming increasingly important in the pharmaceuticals market due to their use to treat previously intractable diseases. The global biological market is worth approximately US$276 billion, and in 2018 seven of the top 10 best-selling drugs were biologicals compared with only three in 2008 [1].
The cost of biologicals in Canada
The top 10 selling originator biological drugs accounted for over half of all biological sales in Canada in 2018, new data reveal.
US biosimilars pipeline for growth hormone and infertility drugs
Global spending on medicines reached US$1 trillion in 2014 and was expected to rise to US$1.2 trillion by 2017 [1], with biologicals making up an increasing part of this total due to their use to treat previously intractable diseases. In fact, spending on biologicals has doubled since 2007 and growth has outstripped that of total sales of pharmaceuticals by a significant margin. The global biological market is worth approximately US$276 billion, and in 2018 seven of the top 10 best-selling drugs were biologicals compared with only three in 2008 [2].
Analysis of biological sales for OECD countries
Data on biological sales for 2018 show that the US tops the list of Organisation for Economic Co-operation and Development (OECD) countries in terms of both per capita sales and share of sales. The data are provided by the Government of Canada in a May 2020 report and show that biologicals account for almost a third of total pharmaceutical sales in Canada.
US biosimilars pipeline for supportive care, oncology and TNF inhibitors
Biologicals represent many of the most promising new therapies for previously intractable diseases and are becoming increasingly important in the pharmaceuticals market. The global biological market is worth approximately US$276 billion, and in 2018 seven of the top 10 best-selling drugs were biologicals compared with only three in 2008 [1].
